CD28 and neoplasm: When PD-L1 expression is upregulated on tumor cells, immune therapy mediated by PD-1/PD-L1 antibodies may enhance the TCR signaling and CD28 signaling of Tregs, thereby activating Tregs and enhancing their inhibitory functions, resisting tumor immunity and ultimately leading to the occurrence of hyper-progressive disease (HPD).